A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs) Meeting Abstract
| Authors: | Johnson, M. L.; Yu, H. A.; Hart, E. M.; Worden, R.; Rademaker, A.; Gupta, R.; Miller, C.; Patel, J. D.; Kris, M. G.; Miller, V. A.; Riely, G. J. |
| Abstract Title: | A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs) |
| Meeting Title: | 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2012 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-05-20 |
| Language: | English |
| ACCESSION: | WOS:000318009802513 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2012.30.15_suppl.3083 |
| Notes: | Meeting Abstract: 3083 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work